Innoviva Other Long-Term Assets 2010-2024 | INVA

Innoviva other long-term assets from 2010 to 2024. Other long-term assets can be defined as field containing the sum of all non-current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
Innoviva Annual Other Long-Term Assets
(Millions of US $)
2023 $3
2022 $4
2021 $0
2020 $0
2019 $0
2018 $0
2017 $0
2016 $0
2015 $0
2014 $18
2013 $8
2012 $3
2011 $3
2010 $4
2009 $5
Innoviva Quarterly Other Long-Term Assets
(Millions of US $)
2024-09-30 $3
2024-06-30 $3
2024-03-31 $3
2023-12-31 $3
2023-09-30 $3
2023-06-30 $4
2023-03-31 $4
2022-12-31 $4
2022-09-30 $5
2022-06-30 $1
2022-03-31 $0
2021-12-31 $0
2021-09-30 $0
2021-06-30 $0
2021-03-31 $0
2020-12-31 $0
2020-09-30 $0
2020-06-30 $0
2020-03-31 $0
2019-12-31 $0
2019-09-30 $0
2019-06-30 $0
2019-03-31 $0
2018-12-31 $0
2018-09-30 $0
2018-06-30 $0
2018-03-31 $0
2017-12-31 $0
2017-09-30 $0
2017-06-30 $0
2017-03-31 $0
2016-12-31 $0
2016-09-30 $0
2016-06-30 $0
2016-03-31 $0
2015-12-31 $0
2015-09-30 $16
2015-06-30 $17
2015-03-31 $17
2014-12-31 $18
2014-09-30 $21
2014-06-30 $23
2014-03-31 $9
2013-12-31 $8
2013-09-30 $7
2013-06-30 $8
2013-03-31 $9
2012-12-31 $3
2012-09-30 $3
2012-06-30 $3
2012-03-31 $3
2011-12-31 $3
2011-09-30 $4
2011-06-30 $4
2011-03-31 $4
2010-12-31 $4
2010-09-30 $4
2010-06-30 $5
2010-03-31 $5
2009-12-31 $5
2009-09-30 $6
2009-06-30 $6
2009-03-31 $9
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $1.195B $0.310B
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $692.744B 71.75
Novo Nordisk (NVO) Denmark $460.555B 33.21
Johnson & Johnson (JNJ) United States $368.366B 14.94
AbbVie (ABBV) United States $294.353B 15.49
Merck (MRK) United States $244.211B 16.23
Novartis AG (NVS) Switzerland $211.084B 14.03
AstraZeneca (AZN) United Kingdom $197.819B 16.83
Pfizer (PFE) United States $142.241B 9.73
Sanofi (SNY) $121.816B 11.03